Surveillance for Therapeutic Inequivalence in Taiwan Area of China

Abstract

Abstract: Objective To share the experiences of surveillance for therapeutic inequivalence (TIE) in Taiwan area of China. Methods Based on the related data, TIE related issues such as definition, procedures for report and assessment, suspected reported cases, and active surveillance mechanism in Taiwan area of China were all introduced. Results There were 488 TIE reported cases from 2009 to 2014 in Taiwan area of China, only one case was found related to the drug of levothyroxine tablet after assessing all the TIE reported cases. Conclusion Now TIE surveillance is an important part of drug safety surveillance, which plays more and more roles in ensuring the safety of drug use as well as improving the quality of drug in Taiwan area of China.

Key words: therapeutic inequivalence, surveillance, Taiwan area of China

CLC Number:

CHEN Zhi-dong . Surveillance for Therapeutic Inequivalence in Taiwan Area of China [J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 28-31.

References

[1] 陈志东. 中国台湾地区药品不良品监测的现状[J]. 中国药物警戒 , 2015, 12(8): 476-478.
[2] FDA. Update:Budeprion XL 300 mg Not Therapeutically Equivalent to Wellbutrin XL 300 mg[EB/OL].(2012-10-03)[2015-10-25]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformati onforPatientsandProviders/ucm322161.htm.
[3] Mastoraki E, Michalopoulos A, Kriaras I, et al. Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime[J]. J Infect, 2008, 56(1): 35-39.
[4] 郁庆华, 谢冉行. 开展仿制药质量一致性评价的探讨[J]. 上海医药 , 2014, 35(7): 49-53.
[5] 何志高, 翟晓波, 鲍思蔚, 等. 国产与进口头孢哌酮 /舒巴坦治疗下呼吸道感染疗效比较 [J].中国药房 , 2010, 21(2): 157-158.
[6] 朱爱江 .两种不同厂家的亚胺培南西司他汀钠治疗重症感染的成本 -效果分析[J]. 广东医药 ,2007, 38(1): 68-69.
[7] 谢沐风. 对国务院《关于印发国家国家药品安全十二五规划通知》的解读与思考[J]. 药品评价 , 2012, 9(20): 6-10.
[8] Center for Drug Evaluation and Research, FDA. Orange Book Preface: Approved Drug Products with Therapeutic Equivalence Evaluations. 34th Edition[EB/OL]. (2015-10-25)[2015-10-25] . http://www.fda. gov/Drugs/Development ApprovalProcess/ucm079068.htm.
[9] 曾雅屏. 药品不良品与药品疗效不等通报作业介绍 [EB/OL]. (2014-06-07)[2015-10-25]. http://hlm.tzuchi.com.tw/drug/images/stories/files/DownloadPharm/ADR10306073.pdf.
[10] 中国台湾地区行政院发言人办公室. 中国台湾地区 2012施政年鉴[M]. 台北: 行政院, 2013: 287.
[11] 中国台湾地区行政院新闻传播处. 中国台湾地区2013 施政年鉴[M]. 台北: 行政院, 2014: 415.
[12] 中国台湾地区行政院新闻传播处. 中国台湾地区2014 施政年鉴[M]. 台北: 行政院, 2015: 381.
[13] 詹孟儒, 杨博文, 陈可欣, 等. 上市后药品疗效相等性监控机制之现状与展望[J]. 食品药物研究年报, 2012, (3): 198-203.
[14] 黄靖雅, 何露菁. 某医学中心评估药品疗效不等安全方法探讨[J]. 药物安全简讯, 2011, 35: 12-17.

[1]	ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
[2]	CHEN Chenxin, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, HE Jia. Combination of zero-inflated model and Dirichlet process in detection of adverse reaction signals during post-marketing surveillance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 651-654.
[3]	PAN Zhemin, XU Sheng, ZHENG Yi, CHEN Chenxin, LIU Yongmei, ZHANG Pengpeng, YE Xiaofei, HE Jia. Comparison of likelihood ratio tests in post-marketing safety surveillance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 655-660.
[4]	ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing. Advances in studies on post-market safety data sources and signal detection for medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
[5]	WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
[6]	SUN Yixin, LIU Zhike, ZHAN Siyan. Scoping review of near real-time surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 61-67.
[7]	FENG Jingnan, ZHAO Houyu, LIU Zhike, ZHAN Siyan. Self-controlled tree temporal scan statistic in active surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 68-73.
[8]	LIU Zhike, ZHAN Siyan. Progress in applications of self-controlled designs in association study of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
[9]	ZHONG Lumiao, DU Juan, DENG Hua, WANG Yafeng, QIU Ping, ZENG Linggui. Thoughts on design and quality management of active safety surveillance research of traditional Chinese medicine injections initiated by Marketing Authorization Holder [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 994-998.
[10]	SHEN Chuanyong, SONG Yana, ZHAO Yan, ZHENG Lijia, ZHAO Yifei, LI Dong. Thoughts on constructing vigilance system of Chinese medical device in the new era [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 697-701.
[11]	TENG Yingying, LI Chaiquan, XU Yang, TANG Xun, GAO Pei. Progress in the application of real-world data in post-market surveillance of medical devices [J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 233-238.
[12]	ZHAO Yifei, ZHAO Yan, DONG Fang, ZHENG Lijia, LI Dong, SONG Yana. Introduction and inspiration of international medical device regulators forum patient registry guidelines [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1091-1096.
[13]	MENG Ruogu, ZHUO Lin, QIAO Rui, LIU Yuqiang, SUN Feng, ZHAN Siyan. Application Values of Real-World Evidence in Post-Marketing Surveillances and Evaluation for Drug Safety [J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 624-627.
[14]	CHEN Feng. Latest Development of International Pharmacovigilance and Its Implications [J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 867-870.
[15]	LI Xiaoyang, GUO Daihong, LIU Siyuan, YANG Hongyi, YAO Chong, QI Zhen. Automatic Surveillance of Cases of Cefoperazone Sodium and Sulbactam Sodium-related Thrombocytopenia [J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 890-893.